Quarterly report pursuant to Section 13 or 15(d)

DISCONTINUED OPERATIONS

v3.24.3
DISCONTINUED OPERATIONS
6 Months Ended
Jun. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATIONS

3. DISCONTINUED OPERATIONS

During September 2023, the Company’s Board of Directors initiated a process to explore strategic alternatives for the business. In consultation with financial and legal advisors, a comprehensive strategic review process began immediately and evaluated a broad range of options to maximize shareholder value.  As part of this review process, Assure’s board of directors agreed to conduct an auction process for the sale of its clinical operations.  As of the filing date of this Quarterly Report on Form 10Q, Assure is providing limited IONM services in Arizona and Montana.

On March 26, 2024, the Company closed the sale of certain clinical assets with National Neuromonitoring Services, LLC for up to $4.5 million, of which $2.3 million was paid in cash at the initial closing and up to an additional $2.2 million to be paid in relation to a potential earnout payment tied to case volume from the acquired assets during the 12-month period following the initial closing. The asset sale includes most of the Company’s healthcare facility contracts and clinical equipment, and a majority of the Company’s clinical employees. The Company retained certain of its assets, including but not limited to, its accounts receivable, certain clinical employees, its employees in the revenue cycle management team and management and office personnel.

As a result of the corporate actions described above, the Company’s technical and professional services meet the criteria to be considered “held for sale.” Accordingly. the assets associated with these services were classified and reflected on our consolidated balance sheets as “held for sale” as of December 31, 2023, and their results of operations are classified as “discontinued operations” in the condensed consolidated statements of operations for the three and six months ended June 30, 2024, and 2023. Since the sale of clinical assets closed on March 26, 2024, the assets held for sale balance was zero as of June 30, 2024. During June 2024, the Company recorded arbitration revenue from discontinued operations originating from professional services which qualified for federal or state arbitration under the no-surprises act.  

The following table presents the major classes of assets of the discontinued operations as of December 31, 2023 (stated in thousands)

    

December 31, 

2023

Fixed assets

$

311

Finance lease right of use asset, net

118

Intangibles, net

 

98

Goodwill

 

1,910

Total assets

$

2,437

The following table summarizes the results of operations of the discontinued operations (stated in thousands): 

Three Months Ended June 30, 

Six Months Ended June 30, 

2024

    

2023

2024

    

2023

Revenue

  

 

  

  

 

  

Technical services

$

240

$

98

$

1,558

$

1,332

Professional services

3,684

490

4,995

2,364

Other

 

(21)

 

507

 

17

 

836

Revenue, net

3,903

1,095

6,570

4,532

Cost of revenues, excluding depreciation and amortization

 

309

 

2,705

 

2,672

 

5,399

Gross margin

 

3,594

 

(1,610)

 

3,898

 

(867)

Operating expenses

Sales and marketing

 

1

 

69

 

55

 

197

Depreciation and amortization

 

 

183

 

 

365

Total operating expenses

 

1

 

252

 

55

 

562

Income from discontinued operations

 

3,593

 

(1,862)

 

3,843

 

(1,429)

Other income (expense)

Gain on sale of assets

666

Interest expense

 

 

(18)

 

(8)

 

(26)

Total other income (expense)

 

 

(18)

 

658

 

(26)

Income from discontinued operations

3,593

(1,880)

4,501

(1,455)

Income tax expense

Net income from discontinued operations

$

3,593

$

(1,880)

$

4,501

$

(1,455)